Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

NCT03420742 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03420742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03420742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2019
Completion date
April 29, 2021
Enrollment
24 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, advanced alk+ or ros1+non-small-cell lung, neoplasm, advanced alk+ or ros1+solid tumors